All aCGH data files were deposited into the GEO database (accession number: GSE62940).

Introduction {#sec001}
============

Ionizing radiation is an established risk factor for breast cancer, and risk increases linearly with dose \[[@pone.0116078.ref001]\]. Breast cancer is among the most radiogenic tumors identified so far among the atomic-bomb survivors \[[@pone.0116078.ref002]\]. The greatest relative risk related to radiation exposure was observed for breast cancer among women who were exposed at a young age \[[@pone.0116078.ref003],[@pone.0116078.ref004]\]. Similarly, breast cancer is the second most common primary cancer among childhood cancer survivors, following only basal cell carcinoma of the skin \[[@pone.0116078.ref005]\]. In the survivors, the odds ratio for breast cancer increased linearly with radiation dose, and breast cancer was diagnosed at young ages (median, 35.9 years; range, 20.9 to 49.6 years) \[[@pone.0116078.ref006]\]. A recent analysis of 1,200 women participating in the Childhood Cancer Survivor Study (CCSS) showed that 25% of those who received \>20 gray (Gy) to the chest area developed breast cancer by age 50; among women who received lower doses of radiation (10--19 Gy), 7% developed breast cancer by age 40, versus a less than 2% chance of developing breast cancer by age 50 in the general population \[[@pone.0116078.ref007]\].

Radiation-associated breast carcinogenesis appears to be a highly complex phenomenon and likely involves accumulating genetic and epigenetic changes. In a recent study characterizing copy number alteration (CNA) and expression profiles in 2,000 breast tumors, Curtis et al. showed that CNAs were associated with profound changes in gene expression through both *cis*- and *trans*-effects \[[@pone.0116078.ref008]\]. The joint clustering of gene expression and CNA profiles revealed novel breast cancer subtypes that refined previously identified molecular subtypes defined by expression-only profiling. These findings suggest that identifying CNA regions may provide a powerful tool to investigate the molecular basis of radiation-associated breast cancer.

Epidemiologic studies of radiation-exposed cohorts have been primarily descriptive. Molecular events responsible for the development of radiation-associated breast cancer are largely unknown, although recent studies demonstrated that radiation-associated breast tumors were characterized by a high degree of proliferation, high frequency of gene amplifications, in particular HER2 amplification, and enriched with basal-like tumors \[[@pone.0116078.ref009]--[@pone.0116078.ref011]\]. In this study, we used comparative genomic hybridization arrays (array-CGH) to characterize the CNA profile in breast tumor tissues collected from CCSS cases, the majority of whose breast cancer were radiation related \[[@pone.0116078.ref006]\], to identify possible distinct genomic aberrations related to radiation exposure.

Methods {#sec002}
=======

Study population {#sec003}
----------------

Data and biologic specimens for the current analysis came from the CCSS, a retrospective cohort study of 14,135 five-year survivors of childhood cancer (age at diagnosis \< 21 years) who were diagnosed and treated at any of 26 collaborating institutions in the United States or Canada between January 1, 1970 and December 31, 1986. Eligible childhood cancer diagnoses included leukemia, central nervous system cancer, Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), renal cancer, neuroblastoma, soft tissue sarcoma or bone sarcoma. The overall study design and characteristics of the cohort were described in detail previously \[[@pone.0116078.ref012]\]. Patients included in the present study were CCSS cases included in a previous analysis of breast cancer risk \[[@pone.0116078.ref006]\] and additional cases diagnosed subsequent to that study. The CCSS study was approved by human subjects review committees at each participating institution. All study participants provided informed consent. The current study of using de-identified archived tumor tissue was exempted from review by the National Institutes of Health Office of Human Subject Research.

Radiation dosimetry {#sec004}
-------------------

Radiation dose to the presumed site of origin of the breast cancer was estimated for the previous study \[[@pone.0116078.ref006]\] by medical physicists using radiotherapy records collected for the CCSS cohort \[[@pone.0116078.ref013]\]. Detailed tumor site-specific dosimetry was not available for the newly identified breast cancer cases. For consistency, we report maximal chest dosage for all cases.

Pathology review {#sec005}
----------------

Most of the breast cancers in the CCSS cohort were self-reported by the participants via a periodic questionnaire. A small minority of cases were first discovered from other medical records being collected. Following self-report, an investigation was made to obtain the pathology report and to request the participant's permission to use paraffin material from their tumor for research. Immunohistochemical (IHC) staining of estrogen receptor (ER) and Ki-67 were performed in a diagnostic pathology laboratory using a Ventana autostainer (Ventana Medical Systems, Inc., Tucson, AZ). The cutoff for Ki-67 low versus high proliferative index was positive staining of 10% cancer cell nuclei.

Array-CGH {#sec006}
---------

Archival formalin-fixed paraffin-embedded (FFPE) tumor blocks were identified from 49 breast cancer cases (41 invasive and 8 *in situ*) in the CCSS cohort. Ten 5-μm unstained tumor sections were used for DNA extraction with enrichment for tumor cells by micro-dissection. Sufficient DNA (1 μg) was obtained from 38 cases. Test and reference DNA (from Promega, Madison, WI) were labeled with Cy5 and Cy3, respectively, and co-hybridized to Agilent CGH arrays containing 180,000 probes tiled across the genome. The intensity of the two fluorescent dyes that reflects chromosomal imbalances between test and reference samples was extracted using Agilent Feature-Extraction software. The log2 ratio was then created for each probe and was used as input to Nexus Copy Number (Biodiscovery, Hawthorne, CA). The Rank Segmentation algorithm (significant threshold = 1 x 10^--6^) was used to identify copy number alterations at the probe level. Low-level copy number gains and losses were defined as absolute log2 ratios larger than 0.3. Amplifications were defined as log2 ratios larger than 1. For example, human epidermal growth factor receptor 2 (HER2, ERBB2) amplification was defined as log2 ratios \> 1 for at least 5 consecutive probes in the 17q12 region containing the HER2 gene. Both objective and subjective measures of data quality were used. Among 38 tumors analyzed, 6 had low quality array-CGH data, mostly because of low signal-to-noise ratio (Nexus quality score \> 0.3 and/or by visualization), and were removed from further analysis (high quality scores suggest elevated noise to signal ratio). The average quality score of remaining 32 samples was 0.14 (range: 0.06--0.28), which was within the acceptable range recommended by Nexus Copy Number.

Statistical analysis {#sec007}
--------------------

Differences between chest radiation exposure with regard to CGH profile (amplifier vs. non-amplifier), ER status, tumor grade, and Ki-67 status were examined using the chi-square test. The Fisher's exact test was used when expected number of samples in any comparison group was less than 5.

Results {#sec008}
=======

In total, array-CGH data was obtained from 32 CCSS cases whose characteristics are shown in Tables [1](#pone.0116078.t001){ref-type="table"} and [2](#pone.0116078.t002){ref-type="table"}. The majority of these cases (N = 21) had HL as the first cancer and the other 11 cases had NHL, bone cancer, leukemia, soft tissue sarcoma, or kidney cancer. Actual dose to the site where the breast cancer developed and systemic chemotherapy doses are available for most of these cases (30 for radiation treatment (RT) and 32 for chemotherapy). Among 30 cases with known radiation status, 21 received radiation directly to the chest (up to 57 Gy), 1 case had RT, but not to the chest or an adjacent body region, 3 cases had RT that included arm, neck or abdomen but not chest, and 5 cases had no RT. Age at diagnosis of the first cancer for all CCSS cases in this study was between 12 and 20 years; therefore, age at radiation exposure was young for all members of this cohort. Among these cases, 26 were invasive ductal carcinoma, two were invasive lobular carcinoma, three were ductal carcinoma *in situ* (DCIS), and one had both *in-situ* ductal and *in-situ* lobular carcinoma. Most of these cases (N = 29) had early-onset breast cancer (before age 45), invasive ductal tumors (N = 26), ER-positive staining (N = 16 of 25 invasive, 3 of 3 for *in situ*), and high proliferation as indicated by high Ki-67 staining (N = 16 of 19 invasive, 1 of 3 *in situ*).

10.1371/journal.pone.0116078.t001

###### Patient characteristics and treatment of CCSS cases included in this study.

![](pone.0116078.t001){#pone.0116078.t001g}

  Subject   Type 1st cancer       Age at 1st cancer   Chemo   Chest RT   MaxChest dosage (Gy)[^a^](#t001fn002){ref-type="table-fn"}
  --------- --------------------- ------------------- ------- ---------- ------------------------------------------------------------
  CCSS1     HL                    13                  No      Yes        45
  CCSS2     HL                    12                  No      Yes        46
  CCSS3     HL                    15                  No      Yes        44
  CCSS4     HL                    17                  No      Yes        50
  CCSS5     HL                    18                  Yes     Yes        45
  CCSS6     HL                    19                  Yes     Yes        45
  CCSS7     HL                    9                   Yes     No         SL
  CCSS8     HL                    10                  No      Yes        35
  CCSS9     HL                    19                  No      Yes        44
  CCSS10    HL                    18                  No      UNK        UNK
  CCSS11    HL                    20                  Yes     No         SH
  CCSS12    HL                    18                  Yes     Yes        42
  CCSS13    HL                    14                  No      Yes        41
  CCSS14    HL                    14                  No      Yes        44
  CCSS15    HL                    15                  No      Yes        44
  CCSS16    HL                    15                  No      Yes        51
  CCSS17    HL                    10                  No      Yes        45
  CCSS18    HL                    15                  No      No         0
  CCSS19    HL                    14                  Yes     Yes        35
  CCSS20    HL                    20                  Yes     Yes        38
  CCSS21    HL                    19                  No      Yes        41
  CCSS22    NHL                   20                  Yes     No         SH
  CCSS23    Bone cancer           16                  Yes     No         SH
  CCSS24    Kidney(Wilms)         15                  Yes     Yes        18
  CCSS25    Kidney(Wilms)         10                  Yes     Yes        14
  CCSS26    Bone cancer           16                  No      Yes        15
  CCSS27    Leukemia              14                  Yes     No         0
  CCSS28    Leukemia              15                  Yes     No         0
  CCSS29    Bone cancer           13                  No      No         0
  CCSS30    NHL                   17                  Yes     UNK        UNK
  CCSS31    Soft tissue sarcoma   13                  Yes     Yes        32
  CCSS32    Kidney(Wilms)         15                  Yes     No         0

Abbreviations: HL = Hodgkin lymphoma, NHL = non-Hodgkin lymphoma, RT = radiotherapy, UNK = unknown.

^a^0 = no direct treatment to the chest, UNK = unknown dose, \>0 and \< 70 Gy = direct treatment to the chest, SL = (low scatter) patient had RT, but not to the chest or an adjacent body region, SH = (high scatter) patient had RT that included arm, neck or abdomen but not chest.

10.1371/journal.pone.0116078.t002

###### Breast tumor characteristics of CCSS cases included in this study.

![](pone.0116078.t002){#pone.0116078.t002g}

  Subject   Age at BC   Type BC    Histology               Grade[^a^](#t002fn002){ref-type="table-fn"}   ER         Ki-67
  --------- ----------- ---------- ----------------------- --------------------------------------------- ---------- -------
  CCSS1     27          Invasive   Ductal                  UNK                                           Negative   High
  CCSS2     39          Invasive   Ductal                  Intermediate                                  Positive   Low
  CCSS3     38          Invasive   Ductal                  High                                          Negative   High
  CCSS4     35          In Situ    DCIS+LCIS               Low                                           Positive   Low
  CCSS5     38          Invasive   Ductal                  High                                          Negative   High
  CCSS6     39          Invasive   Ductal                  Intermediate                                  Positive   High
  CCSS7     30          Invasive   Ductal                  High                                          Positive   High
  CCSS8     31          Invasive   Ductal                  Low                                           Positive   Low
  CCSS9     49          Invasive   Invasive locular+DCIS   UNK                                           Positive   High
  CCSS10    39          In Situ    DCIS                    High                                          Positive   Low
  CCSS11    38          Invasive   Ductal                  High                                          ND         High
  CCSS12    44          Invasive   Ductal                  High                                          Negative   High
  CCSS13    36          Invasive   Ductal                  Intermediate                                  Positive   High
  CCSS14    45          Invasive   Ductal                  High                                          Negative   High
  CCSS15    36          Invasive   Lobular                 Intermediate                                  Positive   High
  CCSS16    38          Invasive   Ductal                  Intermediate                                  Positive   ND
  CCSS17    37          In Situ    DCIS                    Intermediate                                  Positive   High
  CCSS18    42          Invasive   Ductal                  High                                          Negative   High
  CCSS19    40          Invasive   Ductal                  High                                          Positive   High
  CCSS20    48          Invasive   Ductal                  High                                          Positive   High
  CCSS21    40          Invasive   Ductal                  High                                          Positive   High
  CCSS22    42          Invasive   Ductal                  Intermediate                                  Negative   High
  CCSS23    42          Invasive   Ductal                  Intermediate                                  Positive   ND
  CCSS24    40          In Situ    DCIS                    High                                          ND         ND
  CCSS25    37          Invasive   Ductal                  UNK                                           ND         ND
  CCSS26    42          Invasive   Ductal                  Intermediate                                  Positive   ND
  CCSS27    40          Invasive   Ductal                  High                                          Negative   ND
  CCSS28    48          Invasive   Ductal                  Low                                           Positive   ND
  CCSS29    40          Invasive   Ductal                  UNK                                           Positive   ND
  CCSS30    42          Invasive   Ductal                  Low                                           Positive   Low
  CCSS31    42          Invasive   Ductal                  UNK                                           ND         ND
  CCSS32    37          Invasive   Ductal                  High                                          Negative   ND

Abbreviations: BC = breast cancer, DCIS = ductal cell in situ, ER = estrogen receptor, ND = not determined, UNK = unknown.

^a^Grade: low = well differentiated or grade I, intermediate = moderately differentiated or grade II, high = poorly differentiated or grade III.

[Table 3](#pone.0116078.t003){ref-type="table"} shows the CNA profile for each case, listing the most common amplified genes or regions and low-level copy number changes involving whole or parts of chromosomes. A detailed list of CNAs is shown in Table A in [S1 File](#pone.0116078.s001){ref-type="supplementary-material"}. Among the 28 invasive cases with array-CGH data, 5 cases showed "simple" genomic changes characterized by very few copy number changes other than gain of 1q and loss of 16q; 5 cases displayed a more "complex" profile with extensive low-copy number changes but with no high-level amplifications. The majority of CCSS cases (N = 18) displayed amplifications in multiple regions ([Table 3](#pone.0116078.t003){ref-type="table"}, Table A in [S1 File](#pone.0116078.s001){ref-type="supplementary-material"}). Among the amplifiers, the majority (N = 16) showed a "complex-amplifier" profile which is characterized by the presence of both low copy number changes and high-level amplifications ([Fig. 1](#pone.0116078.g001){ref-type="fig"}). The four *in situ* cases showed similar CNA profiles (1 simple, 3 amplifier), and we combined them with invasive cases in subsequent analyses. The most frequent low-copy number changes were the gains of 1q, 3q, 6p, 8q, 16p, and 17q, and losses of 3p, 6q, 8p, 9p, 10q, 11q, 16q and 17p. The most frequent amplifications were 17q12 (containing HER2, n = 12 \[38%\]), 17q21--24 (n = 10 \[31%\]), 11q13 (containing CCND1, n = 7 \[22%\]), 8p11.2 (n = 7 \[22%\]), 8p12 (containing FGFR1, n = 5 \[16%\]), and 8q24 (containing MYC, n = 5 \[16%\]). Among 7 cases with HER2 IHC data available, results from IHC and arrayCGH were consistent for all but one sample ([Table 3](#pone.0116078.t003){ref-type="table"}).

![Array-CGH images of CCSS cases displaying "complex-amplifier" genomic profiles.\
Test and reference DNA were labeled with different dyes and co-hybridized to Agilent CGH arrays containing 180,000 probes tiled across the genome. The chromosome number is shown at the bottom of the figure. Y axis shows the log2 ratios. Low-level copy number gains and losses were defined as absolute log2 ratios larger than 0.3. Amplifications were defined as log2 ratios larger than 1.](pone.0116078.g001){#pone.0116078.g001}

10.1371/journal.pone.0116078.t003

###### ArrayCGH profile and molecular subtypes of CCSS cases included in this study.

![](pone.0116078.t003){#pone.0116078.t003g}

  Subject   CGH subtype[^a^](#t003fn001){ref-type="table-fn"}   Recurrent CNAs                                                                                Subtype[^b^](#t003fn002){ref-type="table-fn"}
  --------- --------------------------------------------------- --------------------------------------------------------------------------------------------- ------------------------------------------------
  CCSS1     Amplifier                                           HER2 amp, CCND1 amp, 1p loss, 3p loss, 5p loss, 6q loss, 8p loss, 9p loss, 17p loss           ER-HER2+
  CCSS2     Amplifier                                           CCND1 amp, 16p gain, 8p loss, 16q loss                                                        Luminal
  CCSS3     Amplifier                                           8p11.2amp, 8q21--23amp, 12q12amp, 19q12--13.2amp, 10q loss                                    ER-HER2-[^c^](#t003fn003){ref-type="table-fn"}
  CCSS4     Simple                                              16q loss                                                                                      Luminal
  CCSS5     Amplifier                                           FGFR1 amp, 8q gain, 3p loss, 8p loss,17p loss                                                 ER-HER2-
  CCSS6     Amplifier                                           FGFR1 amp, CCND1 amp, 1q gain, 6p gain, 16p gain                                              Luminal
  CCSS7     Amplifier                                           HER2 amp, ZNF217 amp, 1q gain, 8q gain, 16p gain, 3p loss, 8p loss                            ER+HER2+[^c^](#t003fn003){ref-type="table-fn"}
  CCSS8     Amplifier                                           MYC amp, ZNF217 amp, 16p gain, 3p loss, 16q loss                                              Luminal
  CCSS9     Amplifier                                           HER2 amp, 6q loss, 16q loss                                                                   ER+HER2+[^c^](#t003fn003){ref-type="table-fn"}
  CCSS10    Amplifier                                           CCND1 amp, 1q gain, 8q gain, 16p gain, 6q loss, 8p loss, 17p loss                             Luminal
  CCSS11    Simple                                              1q gain, 3q gain, 10q gain                                                                    ND
  CCSS12    Amplifier                                           CCND1 amp, 16p gain                                                                           ER-HER2-[^c^](#t003fn003){ref-type="table-fn"}
  CCSS13    Simple                                              16q loss                                                                                      Luminal
  CCSS14    Amplifier                                           HER2 amp, 1q gain, 6q loss, 8p loss, 9p loss, 10q loss                                        ER-HER2+
  CCSS15    Complex                                             1q gain, 6p gain, 17q gain, 3p loss, 6q loss, 13q loss, 17p loss                              Luminal
  CCSS16    Amplifier                                           MYC amp, FGFR1 amp, 10q loss, 16q loss                                                        Luminal
  CCSS17    Amplifier                                           HER2 amp                                                                                      ER+HER2+
  CCSS18    Amplifier                                           HER2 amp, 3q gain, 3p loss, 9p loss                                                           ER-HER2+
  CCSS19    Complex                                             1q gain, 17q gain, 1p loss, 6q loss, 13q loss, 16q loss, 17p loss                             Luminal
  CCSS20    Simple                                              1q gain, 18q loss                                                                             Luminal[^c^](#t003fn003){ref-type="table-fn"}
  CCSS21    Amplifier                                           HER2 amp, CCND1 amp, FGFR1 amp, MYC amp, 8q gain, 16p gain, 8p loss, 16q loss, 17p loss       ER+HER2+
  CCSS22    Amplifier                                           HER2 amp                                                                                      ER-HER2+
  CCSS23    Amplifier                                           CCND1 amp, 1q gain, 16p gain                                                                  Luminal
  CCSS24    Amplifier                                           HER2 amp, 9p loss, 10q loss                                                                   ND
  CCSS25    Amplifier                                           FGFR1 amp, HER2 amp                                                                           ND
  CCSS26    Simple                                              1p loss, 10q loss                                                                             Luminal[^c^](#t003fn003){ref-type="table-fn"}
  CCSS27    Amplifier                                           HER2 amp, MYC amp, ZNF217 amp, 5p gain, 8q gain, 9q gain, 20q gain, 8p loss                   ER-HER2+[^c^](#t003fn003){ref-type="table-fn"}
  CCSS28    Simple                                              8q gain                                                                                       Luminal
  CCSS29    Complex                                             3q gain, 8q gain, 9q gain, 17q gain, 1p loss, 3p loss, 6q loss, 9p loss, 10q loss, 16q loss   Luminal
  CCSS30    Complex                                             10p gain, 16p gain, 20p gain, 10q loss, 16q loss                                              Luminal
  CCSS31    Complex                                             1q gain, 1p loss, 3p loss, 6q loss, 9p loss, 11q loss                                         ND
  CCSS32    Amplifier                                           HER2 amp, MYC amp, 8p loss, 9p loss, 17p loss, 11p gain, 17q gain                             ER-HER2+

^a^Array-CGH subtype: simple: very few copy number changes other than gain of 1q and loss of 16q; complex; extensive low copy number changes but with no high-level amplifications; amplifiers: high-level amplifications usually accompanied by low copy number changes.

^b^ER positivity was determined by immunohistochemistry; HER2 positivity was defined by the presence of amplification of 17q12 region (log2 ratio\>1) based on aCGH data.

^c^HER2 IHC status was available. IHC and CGH data were concordant for all but one sample (CCSS20), for which IHC was positive and amplification was negative.

Among 28 cases with ER status available, 15 cases (54%) had luminal tumors, defined as positive for ER by IHC and negative for HER2 amplification; 4 cases (14%) were double positive (ER+ and HER2amp); 6 cases (21%) were ER- and HER2amp; and 3 cases (11%) were double negative (ER-negative and HER2amp-negative) tumors. The frequency of high-level amplifications was significantly lower in ER+ tumors (53% vs. 100% in ER-, p = 0.01). The difference remained significant when taking out the four in situ cases. All nine cases with a simple or complex CGH profile with the absence of amplifications had luminal tumors (ER status was undetermined in one "simple" and one "complex" case). The remaining six luminal tumors were amplifiers, harboring both amplifications (mostly in CCND1) and low-copy changes such as 16p gain and 16q loss. Among ten HER2-amplified tumors with known ER status, ER+ (N = 4) and ER- tumors (N = 6) showed similar CNAs in other chromosome regions. The three cases with double-negative tumors all had "complex-amplifier" CNA profiles.

Copy number changes did not appear to vary by whether the patient received chemotherapy in addition to radiation treatment or not.

Discussion {#sec009}
==========

In this study, we characterized molecular and genetic changes in tumor tissue collected from CCSS breast cancer cases, the majority of whom were treated with chest radiation for a prior tumor when they were under 20 years of age. We found that breast cancers in the majority of these cases were positive for ER (68%, n = 19 out of 22), highly proliferative as indicated by Ki-67 staining (77%, n = 17 out of 22), and frequently had high-level amplifications (66%). The frequency of HER2 amplification appeared to be particularly higher in this irradiated series of cases (38%, n = 12) compared to breast cancer among young women in the general population \[[@pone.0116078.ref014]--[@pone.0116078.ref017]\].

Genomic regions with low-copy gains and losses and high-level gene amplifications among CCSS cases were similar to those reported for breast cancers in the general population, with the most frequent gains on chromosomes 1q, 3q, 6p, 8q, 16p, and 17q; losses on 3p, 6q, 8p, 9p, 10q, 11q, 16q, and 17p; and high-level amplifications of 8p 11.2--12, 8q24, 11q13, 17q12, and 17q21--24. Previous array-CGH studies classified breast tumors into three genomic subtypes (simplex, complex, and amplifier) and found a significant correlation between these genomic subtypes and molecular subtypes defined by gene expression profiles \[[@pone.0116078.ref018],[@pone.0116078.ref019]\]. Using a similar classification scheme, we found that a majority of CCSS cases demonstrated a "complex-amplifier" profile, characterized by the presence of extensive low copy number changes and recurrent amplifications. High-level amplifications have been associated with short telomere length, indicating high genomic instability, and poor prognosis independent of tumor grade and nodal status \[[@pone.0116078.ref018],[@pone.0116078.ref019]\]. The majority of the CCSS cases (17 out of 22) in our study demonstrated proliferation as indicated by Ki-67 staining, suggesting that radiation may induce a highly proliferative subtype of breast cancer through gene amplifications. It is possible that the high frequency of amplifications may be a characteristic of young breast cancer cases instead of being driven by radiation exposure since breast cancers in CCSS survivors occurred at young ages. However, the frequency of HER2 amplification in CCSS cases (38%) was still higher compared to young breast cancer (\<45 years) in the general population (16%−25%) based on a literature search \[[@pone.0116078.ref014]--[@pone.0116078.ref017]\]. In addition, we compared the frequency of the most common amplifications to those in breast cancer cases diagnosed before 45 years of age in The Cancer Genome Atlas (TCGA) Research Network (<http://cancergenome.nih.gov/>) \[[@pone.0116078.ref020]\] as well as in three published studies with accessible age and array-CGH data \[[@pone.0116078.ref021]--[@pone.0116078.ref023]\], and we found that the frequency of most amplifications, in particular, regions containing HER2 and possibly CCND1, still appeared higher compared to breast cancer in the general population (Table B in [S1 File](#pone.0116078.s001){ref-type="supplementary-material"}). Since the vast majority of cases in our study received high-dose radiation and very few cases had no radiation or radiation in other body areas, our study did not have the power in evaluating the radiation dosage in relation to HER2 amplification frequency. However, our data are consistent with the high frequency of HER2 amplification observed in breast cancers among atomic-bomb survivors \[[@pone.0116078.ref010],[@pone.0116078.ref024]\], supporting the view that HER2 amplification may be an important mechanism in radiation-associated breast carcinogenesis.

A gene expression profiling analysis of breast tumors from 22 patients who developed breast cancer after HL suggested that radiation-associated tumors were associated with a higher frequency of basal-like tumors \[[@pone.0116078.ref009]\]. Similarly, a more recent study found that breast cancer patients after radiation therapy were more likely to have triple-negative tumors \[[@pone.0116078.ref011]\]. Using immunohistochemical ER status and HER2 amplification, we classified breast cancers into four subtypes, luminal, ER+/HER2+, ER-HER2+, and double negative. The frequency of ER+ tumors in our study (68%, n = 19 out of 28) is slightly higher compared to breast cancer among young cases in the general population (50--60%) \[[@pone.0116078.ref015],[@pone.0116078.ref017]\], but is consistent with what was reported by Broeks et al. in the study of breast cancer after HL \[[@pone.0116078.ref009]\]. However, in contrast to the enrichment of basal-like or triple-negative tumors observed in previous studies, our results showed that breast tumors from CCSS cases were preferentially of two subtypes: luminal or HER2+, which is in line with what was observed by Castiglioni in breast tumors developed in women irradiated for HL within 4 years of menarche \[[@pone.0116078.ref025]\]. Our data is also consistent with findings from previous reports that radiation-associated breast cancers were characterized by more proliferative and aggressive features \[[@pone.0116078.ref009],[@pone.0116078.ref024]\]. Since each individual study is unavoidably limited by the small sample size, a collaborative effort combining data from multiple such studies is needed to more accurately characterize the distribution of molecular subtypes in radiation-associated breast tumors.

As expected, all cases without amplifications had luminal tumors in our study; however, luminal tumors also demonstrated extensive heterogeneity in genomic changes. In addition to the simple subtype, 5 luminal cases displayed a complex profile, and the remaining 6 luminal cases harbored high-level amplifications (4 had amplifications in CCND1). Our data are consistent with previous findings that the majority of CCND1-amplified tumors were ER+ \[[@pone.0116078.ref026]\]. Recently, a large-scale genomic and transcriptomic analysis of 2,000 breast tumors revealed a high-risk 11q13/14 *cis*-acting luminal subtype that was associated with high mortality \[[@pone.0116078.ref008]\]. This subgroup exhibited high-level amplification in CCND1 as well as alterations in several key cell cycle-related genes, which may be the drivers for the development of this tumor subtype and play a role in its aggressiveness. The higher frequency of ER-positive staining and focal amplifications suggest that breast tumors in CCSS cases may be enriched for a high-risk luminal subtype \[[@pone.0116078.ref027]\].

The major limitations of our study include small sample size, particularly in the non-irradiated group. There were only nine cases without chest radiation and, among them, 4 cases had radiation exposure but not directly to the chest. Therefore, we were not able to conduct a direct "case-control" comparison within the cohort or to model copy number changes against quantitative radiation dosage because of small sample size. However, our study population is unique; most cases had high-dose radiation at early ages and developed breast cancer when they were young. In addition, we characterized genome-wide CNAs as well as ER expression and proliferation status in these cases, which is lacking in the radiation-associated human breast cancer literature.

In conclusion, data from our study are consistent with previous findings that radiation-associated breast cancer might have a distinct pathogenesis, characterized by high frequency of genomic amplifications and high degree of proliferation. Future studies with large numbers of exposed and non-exposed cases are needed to validate these findings to determine the etiologic link between radiation exposure, early age onset, gene amplifications, and highly proliferative breast cancers.
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